National Cooperative Gallstone Study. The effect of chenodeoxycholic acid on lipoproteins and apolipoproteins

John J. Albers, Scott M Grundy, Patricia A. Cleary, Donald M. Small, John M. Lachin, Leslie J. Schoenfield

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Subjects in the National Cooperative Gallstone Study undergoing 12 mo of therapy with chenodeoxycholic acid for the dissolution of gallstones (low-dose, 375 mg/day, n = 252; high-dose, 750 mg/day, n = 253) had a mean increase in serum cholesterol of 20 mg/dl as compared with a 5 mg/dl increase in the placebo group (n = 258). The effect of chenodeoxycholic acid on lipoproteins was determined in a random subset of the high-dose (n = 136) and placebo (n = 143) groups. For men, the mean base-line adjusted estimated low-density lipoprotein cholesterol level at 12 mo was significantly higher in the high-dose group than in the placebo group (159 vs. 148 mg/dl, p < 0.01), whereas among women this difference was not demonstrated. Change in low-density lipoprotein cholesterol level was inversely related to baseline cholesterol to an equivalent degree in each group among men and women. Women in the high-dose group had significantly lower verylow-density lipoprotein cholesterol levels than did the corresponding placebo group (27 vs. 32 mg/dl, p < 0.003). Very-low-density lipoprotein cholesterol levels did not differ significantly between the high-dose and placebo group in men. Treatment did not significantly affect the levels of high-density lipoprotein cholesterol or apoproteins A-I, A-II, or B. Chenodeoxycholic acid therapy produces an increase in total cholesterol and low-density lipoprotein cholesterol but does not alter high-density lipoprotein cholesterol levels.

Original languageEnglish (US)
Pages (from-to)638-646
Number of pages9
JournalGastroenterology
Volume82
Issue number4
StatePublished - 1982

Fingerprint

Chenodeoxycholic Acid
Apolipoproteins
Gallstones
Lipoproteins
Placebos
LDL Cholesterol
Cholesterol
HDL Cholesterol
VLDL Cholesterol
Apoproteins
Therapeutics
Serum

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Albers, J. J., Grundy, S. M., Cleary, P. A., Small, D. M., Lachin, J. M., & Schoenfield, L. J. (1982). National Cooperative Gallstone Study. The effect of chenodeoxycholic acid on lipoproteins and apolipoproteins. Gastroenterology, 82(4), 638-646.

National Cooperative Gallstone Study. The effect of chenodeoxycholic acid on lipoproteins and apolipoproteins. / Albers, John J.; Grundy, Scott M; Cleary, Patricia A.; Small, Donald M.; Lachin, John M.; Schoenfield, Leslie J.

In: Gastroenterology, Vol. 82, No. 4, 1982, p. 638-646.

Research output: Contribution to journalArticle

Albers, JJ, Grundy, SM, Cleary, PA, Small, DM, Lachin, JM & Schoenfield, LJ 1982, 'National Cooperative Gallstone Study. The effect of chenodeoxycholic acid on lipoproteins and apolipoproteins', Gastroenterology, vol. 82, no. 4, pp. 638-646.
Albers, John J. ; Grundy, Scott M ; Cleary, Patricia A. ; Small, Donald M. ; Lachin, John M. ; Schoenfield, Leslie J. / National Cooperative Gallstone Study. The effect of chenodeoxycholic acid on lipoproteins and apolipoproteins. In: Gastroenterology. 1982 ; Vol. 82, No. 4. pp. 638-646.
@article{ecc7e4a8e3044b16acdd203045655cee,
title = "National Cooperative Gallstone Study. The effect of chenodeoxycholic acid on lipoproteins and apolipoproteins",
abstract = "Subjects in the National Cooperative Gallstone Study undergoing 12 mo of therapy with chenodeoxycholic acid for the dissolution of gallstones (low-dose, 375 mg/day, n = 252; high-dose, 750 mg/day, n = 253) had a mean increase in serum cholesterol of 20 mg/dl as compared with a 5 mg/dl increase in the placebo group (n = 258). The effect of chenodeoxycholic acid on lipoproteins was determined in a random subset of the high-dose (n = 136) and placebo (n = 143) groups. For men, the mean base-line adjusted estimated low-density lipoprotein cholesterol level at 12 mo was significantly higher in the high-dose group than in the placebo group (159 vs. 148 mg/dl, p < 0.01), whereas among women this difference was not demonstrated. Change in low-density lipoprotein cholesterol level was inversely related to baseline cholesterol to an equivalent degree in each group among men and women. Women in the high-dose group had significantly lower verylow-density lipoprotein cholesterol levels than did the corresponding placebo group (27 vs. 32 mg/dl, p < 0.003). Very-low-density lipoprotein cholesterol levels did not differ significantly between the high-dose and placebo group in men. Treatment did not significantly affect the levels of high-density lipoprotein cholesterol or apoproteins A-I, A-II, or B. Chenodeoxycholic acid therapy produces an increase in total cholesterol and low-density lipoprotein cholesterol but does not alter high-density lipoprotein cholesterol levels.",
author = "Albers, {John J.} and Grundy, {Scott M} and Cleary, {Patricia A.} and Small, {Donald M.} and Lachin, {John M.} and Schoenfield, {Leslie J.}",
year = "1982",
language = "English (US)",
volume = "82",
pages = "638--646",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - National Cooperative Gallstone Study. The effect of chenodeoxycholic acid on lipoproteins and apolipoproteins

AU - Albers, John J.

AU - Grundy, Scott M

AU - Cleary, Patricia A.

AU - Small, Donald M.

AU - Lachin, John M.

AU - Schoenfield, Leslie J.

PY - 1982

Y1 - 1982

N2 - Subjects in the National Cooperative Gallstone Study undergoing 12 mo of therapy with chenodeoxycholic acid for the dissolution of gallstones (low-dose, 375 mg/day, n = 252; high-dose, 750 mg/day, n = 253) had a mean increase in serum cholesterol of 20 mg/dl as compared with a 5 mg/dl increase in the placebo group (n = 258). The effect of chenodeoxycholic acid on lipoproteins was determined in a random subset of the high-dose (n = 136) and placebo (n = 143) groups. For men, the mean base-line adjusted estimated low-density lipoprotein cholesterol level at 12 mo was significantly higher in the high-dose group than in the placebo group (159 vs. 148 mg/dl, p < 0.01), whereas among women this difference was not demonstrated. Change in low-density lipoprotein cholesterol level was inversely related to baseline cholesterol to an equivalent degree in each group among men and women. Women in the high-dose group had significantly lower verylow-density lipoprotein cholesterol levels than did the corresponding placebo group (27 vs. 32 mg/dl, p < 0.003). Very-low-density lipoprotein cholesterol levels did not differ significantly between the high-dose and placebo group in men. Treatment did not significantly affect the levels of high-density lipoprotein cholesterol or apoproteins A-I, A-II, or B. Chenodeoxycholic acid therapy produces an increase in total cholesterol and low-density lipoprotein cholesterol but does not alter high-density lipoprotein cholesterol levels.

AB - Subjects in the National Cooperative Gallstone Study undergoing 12 mo of therapy with chenodeoxycholic acid for the dissolution of gallstones (low-dose, 375 mg/day, n = 252; high-dose, 750 mg/day, n = 253) had a mean increase in serum cholesterol of 20 mg/dl as compared with a 5 mg/dl increase in the placebo group (n = 258). The effect of chenodeoxycholic acid on lipoproteins was determined in a random subset of the high-dose (n = 136) and placebo (n = 143) groups. For men, the mean base-line adjusted estimated low-density lipoprotein cholesterol level at 12 mo was significantly higher in the high-dose group than in the placebo group (159 vs. 148 mg/dl, p < 0.01), whereas among women this difference was not demonstrated. Change in low-density lipoprotein cholesterol level was inversely related to baseline cholesterol to an equivalent degree in each group among men and women. Women in the high-dose group had significantly lower verylow-density lipoprotein cholesterol levels than did the corresponding placebo group (27 vs. 32 mg/dl, p < 0.003). Very-low-density lipoprotein cholesterol levels did not differ significantly between the high-dose and placebo group in men. Treatment did not significantly affect the levels of high-density lipoprotein cholesterol or apoproteins A-I, A-II, or B. Chenodeoxycholic acid therapy produces an increase in total cholesterol and low-density lipoprotein cholesterol but does not alter high-density lipoprotein cholesterol levels.

UR - http://www.scopus.com/inward/record.url?scp=0020041008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020041008&partnerID=8YFLogxK

M3 - Article

C2 - 6800869

AN - SCOPUS:0020041008

VL - 82

SP - 638

EP - 646

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 4

ER -